10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-FGFR2 / CD332 Reference Antibody (bemarituzumab)

Recombinant Antibody
Catalog # APR10697

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P21802
Reactivity	Human
Clonality	Monoclonal
Isotype	Human IgG1
Calculated MW	144 KDa

Additional Information

Target/Specificity	FGFR2 / CD332
Endotoxin	
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.


Protein Information

Images




Anti- Human FGFR2(bemarituzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.


Anti- Human FGFR2(bemarituzumab) is 100%,




determined by SEC-HPLC.




SNU-16 cells were stained with Anti- Human FGFR2(bemarituzumab), with isotype and secondary-only controls. Flow analysis showed specific binding of the antibody, with an EC50 of 0.5368 ug/mL.



The ADCC activity of anti-human FGFR2 monoclonal antibody (bemarituzumab) was evaluated using a human FGFR2-expressing HEK293 reporter cell line. Results demonstrated a robust induction of ADCC, with a maximum fold increase of approximately 25 compared to baseline.



The ADCC activity of anti-human FGFR2 monoclonal antibody (bemarituzumab) was evaluated using a KATOIII cell line. Results demonstrated a robust induction of ADCC, with a maximum fold increase of approximately 14 compared to baseline.



Anti- Human FGFR2(bemarituzumab) inhibited the tumor growth of SNU-16 on Balb/c nude mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 29.7% at 2 mpk at D62.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.